1. What is the evidence of the effectiveness of peer-based programs to support adherence to highly active antiretroviral therapy (HAART)? 2. What population-related variables may be related to the success of peerbased adherence programs? (e.g. age, race, gender, drug use, homelessness) 3. What approaches have been successfully used to select peers and match them to participants in adherence sup...

Fourteen cases of gynecomastia occurring during highly active antiretroviral therapy (HAART) have been reported in the literature. To date, no specific therapeutic approach has been proposed, and gynecomastia has usually persisted. We report 4 new cases of HAART-induced gynecomastia that were successfully treated with percutaneous dihydrotestosterone gel.

The efficacy of antiretroviral therapy to prevent motherto-child HIV transmission (MTCT) was first established in 1994. In that study by Connor and colleagues (PACTG 076) both mother and infant were treated with long courses of zidovudine, which reduced HIV transmission from 25 to 8% [1]. Since then, improved interventions in industrialized nations have further reduced MTCT rates to less than 2...

In 1997, Taiwan made highly active antiretroviral therapy (HAART) available without cost to HIV-infected persons; in 2001, a national web-based surveillance system was implemented. Healthcare workers use the system to monitor patients' conditions and can intervene when necessary. Free HAART, coupled with the surveillance system, appears to have increased survival rates of HIV-infected persons w...

Introduction Current UK guidelines recommend initiation of HAART in all patients with a CD4 count of <350 cells/mm. The success of this policy depends on early HIV diagnosis. One-third of individuals in the UK have a CD4 cell count <200 cells/mm at diagnosis. According to the European consensus, late presentation for care refers to persons presenting with CD4 cell count <350 cells/mm or present...

CONTENTS INTRODUCTION EPIDEMIOLOGY GROSS ANATOMICAL CHANGES CHANGES PRIMARILY ATTRIBUTABLE TO HIV-1 CHANGES PROBABLY ATTRIBUTABLE TO HIV-1 VIRAL INFECTIONS IN THE COURSE OF HIV-1 INFECTION PARASITIC INFECTIONS FUNGAL INFECTIONS NEOPLASIA IN THE COURSE OF HIV-1 INFECTION FREQUENCY AND TOPOGRAPHICAL DISTRIBUTION OF NEUROPATHOLOGICAL CHANGES IMMUNOHISTOCHEMICAL DEMONSTRATION OF HIV-1: FREQUENCY AN...

Copyright: © 2008 Keiser et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Table 1. Baseline Characteristics of Patients Starting HAART in Khayelitsha and Gugulethu, South Africa and the Swiss HIV Cohort ...

The Berlin patient is the first publicly known case of HIV remission as a result of HIV treatment. The perils of interrupting treatment after it has been initiated are discussed, and case studies of volunteers who have discontinued treatment are described. The case of the Berlin patient has sparked discussion of new treatment strategies that may involve highly active antiretroviral therapy (HAA...